Bicara Therapeutics Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BCAX Nasdaq 2834 www.bicara.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bicara Therapeutics Inc.

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 - Apr 28th, 2025 8:01 pm
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 23rd, 2025 2:00 pm
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Mar 27th, 2025 11:30 am
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 - Mar 25th, 2025 8:45 pm
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth - Mar 12th, 2025 10:44 am
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Feb 24th, 2025 9:01 pm
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - Feb 11th, 2025 9:01 pm
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium - Jan 27th, 2025 1:00 pm
Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia - Jan 8th, 2025 3:16 pm
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 12th, 2024 12:30 pm
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - Nov 11th, 2024 9:01 pm
Opening Day: Another trio of biotech IPOs make Friday debut - Oct 14th, 2024 10:45 am
MBX Biosciences earns Buy rating at three investment firms - Oct 8th, 2024 2:44 pm
RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares - Sep 23rd, 2024 11:05 pm
FMR LLC Acquires New Stake in Bicara Therapeutics Inc - Sep 18th, 2024 7:01 pm
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Sep 17th, 2024 1:13 pm
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Sep 16th, 2024 8:01 pm
TPG-backed Bicara Therapeutics raises $315 million in US IPO - Sep 13th, 2024 1:38 am
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering - Sep 13th, 2024 1:15 am
Three biotechs raise $700M in rare burst of IPO activity - Sep 12th, 2024 11:02 pm